Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

Benzinga Newsdesk www.benzinga.com Negative 85.2%

Neg 85.2% Neu 0% Pos 0%

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.